NDAORALSUSPENSION
Approved
Dec 1993
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
5/8 — Partial
CARAFATE (sucralfate) by AbbVie is clinical pharmacology sucralfate is only minimally absorbed from the gastrointestinal tract. Approved for gastritis. First approved in 1993.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CARAFATE (sucralfate) is an oral aluminum complex suspension approved for gastritis treatment that works through local gastrointestinal action rather than systemic absorption. It forms an ulcer-adherent complex that protects the ulcer site from acid, pepsin, and bile salt attack while inhibiting pepsin activity by 32%. The drug is minimally absorbed, with small amounts excreted renally, and provides 14-16 mEq of acid-neutralizing capacity per gram dose.
$0.002BPart D
LOE ApproachingDeclining
Mature product approaching loss of exclusivity with minimal Part D engagement signals contraction phase; expect smaller, focused teams managing decline.
Mechanism of Action
CLINICAL PHARMACOLOGY Sucralfate is only minimally absorbed from the gastrointestinal tract. The small amounts of the sulfated disaccharide that are absorbed are excreted primarily in the urine. Although the mechanism of sucralfate's ability to accelerate healing of duodenal ulcers remains to be…
Pharmacologic Class:
Aluminum Complex
Indications (1)
Worked on CARAFATE at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.